Conversations in Healthcare

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, speaks with Stephen Russell, CEO of Vyriad. Dr. Russell reveals invaluable insights for those looking for or currently putting together partnership deals. Stephen shares his journey from academia at the Mayo Clinic to founding Vyriad, and eventually partnering with Regeneron for the development of new oncolytic virus treatments for cancer. Learn how Vyriad pivoted their technology to develop antibody tests for COVID-19 during the crisis.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, speaks with Alison Kneen, Senior Vice President, Global Market Access and Head of the Centre of Innovation and Regulatory Science (CIRS) and DRG Abacus. Learn why early and thorough planning is so important for a successful product launch, and how Alison and her team helped one client avoid major pitfalls, even when the odds were stacked against them.

Hosted on Acast. See acast.com/privacy for more information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Nick McCooke, CEO of Longas Technologies. Having been at the forefront of developing next generation sequencing, Nick talks to Mike about his past work, current projects and future predictions for this key technology in the life sciences space. He explains the process and journey he went on to trigger the creation of Solexa, which was later acquired by Illumina, and how next generation sequencing developed and transformed the marketplace after this acquisition. Nick also explains the role NGS has played in the development of Covid-19 solutions around the world, including mapping the viral genome and tracking subsequent mutations. They go onto the discuss the long-read sequencing platform Longas Technologies is currently working on and how this could advance NGS even. Nick also gives his predictions on where NGS could go next, and how it’ll continue to develop and benefit the patient.

Hosted on Acast. See acast.com/privacy for more information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, Part of Clarivate talks to Bob Coughlin, president and CEO of the Massachusetts Biotechnology Council. Bob provides insights from what is unarguably the world’s number one biopharma hotspot. Bob and Mike discuss how the industry has collaborated to counter the most immediate issues the COVID-19 pandemic has raised and how these could inform the future of biopharma. Bob also talks passionately about how partnering with patient groups is key to patient centricity to truly understand the real unmet patient need. 

Hosted on Acast. See acast.com/privacy for more information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Mike Hughes, Senior Director of Epidemiology at DRG. With epidemiology entering our daily vernacular, thanks to the Covid-19 pandemic, Mike gives a definition of what it is, the approaches used to model epidemiology associated with diseases and how it’s beneficial across all stages of research and development in pharma. In particular, they talk about the value epidemiology can bring to decision making and how it can aid in maximizing R&D efforts and investment decisions surrounding pipeline development and go to market plans.

Hosted on Acast. See acast.com/privacy for more information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Sir Mene Pangalos, Executive Vice President at AstraZeneca. Sir Mene talks to Mike about AstraZeneca's learnings from helping Chinese colleagues combat Coronavirus at the end of 2019, and then expanding input as it became a global issue. This includes adapting existing molecules in their pipeline, utilizing their existing capabilities and keeping their supply chain moving. He also explains how the industry has come together like never before to collaborate and share ideas across the board. Sir Mene and Mike also discuss what the new normal for the pharma industry may look like in a post-pandemic world.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Dr Srikanth Rajagopal (or Doc, as he is fondly referred to). Doc, a partner at DRG Consulting, whose areas of expertise include product and portfolio strategy to name a few, chatted to us about common strategic challenges biotechnology companies face during the process of translating a discovery into a tangible medicine. Doc gives invaluable insight for bio-pharma companies who are making development and/or commercializing decisions for their clinical programs both for those developing in house and those considering out licensing. He explores pertinent examples of how companies can go about understanding the commercial opportunity of their efficacious treatments in various scenarios and markets (including orphan indications) and discusses what he calls the 'magic triangle' to get an asset to market as fast as possible.

Hosted on Acast. See acast.com/privacy for more information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Houman Ashrafian, Managing Partner at SV Health Investors. Houman gives an interesting perspective into how and why biotech investment has remained robust throughout the Covid-19 pandemic. He talks to Mike about his proven track record for establishing companies and the factors he looks for when identifying interesting, investable science. Houman also talks about his work on the Dementia Discovery Fund investment committee, the opportunities they look for as well as the lessons the industry can learn from the immune-oncology revolution and how these can be applied to combat other diseases including neurodegenerative conditions, such as dementia. Houman is optimistic about where the UK is in terms of developing sciences, and what we’ll be able to achieve in this unprecedented time of science innovation.

Hosted on Acast. See acast.com/privacy for more information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Joe Panetta, President and CEO of BIOCOM. Joe talks around how BIOCOM has worked closely with government officials to ensure the life science community can continue to function throughout the COVID-19 pandemic, and how they’ve worked with these officials to develop guidance for this community on how they can safely return to work. Joe discusses how COVID-19 has affected funding for biotech companies, the ability to build international relationships with global companies and how new digital practices such as virtual partnering could be a new way of developing these relationships post-pandemic. He also passionately describes how the industry needs to become more patient centric, as it has with COVID-19. 

Hosted on Acast. See acast.com/privacy for more information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Charlotte Allen and Russ Bradford from Parkinson’s Concierge. Russ and Charlotte offer a unique insight into how being a patient centric organisation enables them to help the Parkinson’s Disease community improve their quality of life and understanding of the disease. They talk about the work they’re currently doing to educate the community and their newest partnership with ReMeLife to expand their network globally. As the disease affects each patient differently, they work to raise awareness to organizations working on treating Parkinson’s about the importance of working with patient groups to better understand how to treat the disease.

Hosted on Acast. See acast.com/privacy for more information.